Comparative Pharmacology
Head-to-head clinical analysis: LIVOSTIN versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVOSTIN versus X TROZINE L A.
LIVOSTIN vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine
Antihistamine